Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on EyePoint Pharmaceuticals (EYPT – Research Report) and Zymeworks (ZYME – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EyePoint Pharmaceuticals (EYPT)
JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on EyePoint Pharmaceuticals today and set a price target of $43.00. The company’s shares closed last Monday at $18.34.
According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for EyePoint Pharmaceuticals with a $34.40 average price target, a 100.2% upside from current levels. In a report issued on February 19, Mizuho Securities also maintained a Buy rating on the stock with a $36.00 price target.
See today’s best-performing stocks on TipRanks >>
Zymeworks (ZYME)
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Zymeworks, with a price target of $34.00. The company’s shares closed last Monday at $23.31.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of
Zymeworks has an analyst consensus of Strong Buy, with a price target consensus of $32.80, which is a 45.5% upside from current levels. In a report issued on February 20, Citi also maintained a Buy rating on the stock with a $35.00 price target.
